FORECAST 1. Feasibility of using Organoid Response to find Effective Treatments for patients with Colorectal cancer After failure of Standard Therapy

Not Applicable

Completed

• Conditions: Metastatic Colorectal Cancer; Cancer - Bowel - Back passage (rectum) or large bowel (colon)

• Registration Number: ACTRN12620001353987
• Lead Sponsor: Australasian Gastro-Intestinal Trials Group (AGITG)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-12-15
• Study Completion: 2023-03-15
• Last Update Posted: 27 March 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1.Able to provide informed, voluntary, written consent
2.Have a diagnosis of metastatic colorectal cancer
3.Are able to safely undergo biopsy to provide samples of fresh tumour
4.ECOG performance status of 0-2
5.Have adequate major organ function
6.Fit for further systemic treatment
7.Have failed or are intolerant of standard therapies (excluding trifluridine/tipiracil)
8.Prior systemic treatment must have discontinued at least 2 weeks prior to enrolment onto the study
9.Have a life expectancy of > 3 months
10.Are accessible for follow up and de-identified coded data collection

Exclusion Criteria

1.Have a condition that interferes with their ability to provide informed consent or comply with the protocol
2.Unable to provide tissue samples for any reason

Study & Design

• Study Type: Interventional
• Study Design: Not specified